U.S. markets open in 7 hours 21 minutes
  • S&P Futures

    3,905.50
    +1.75 (+0.04%)
     
  • Dow Futures

    31,440.00
    +19.00 (+0.06%)
     
  • Nasdaq Futures

    12,050.25
    +9.75 (+0.08%)
     
  • Russell 2000 Futures

    1,772.80
    +3.00 (+0.17%)
     
  • Crude Oil

    110.71
    +1.14 (+1.04%)
     
  • Gold

    1,826.70
    +1.90 (+0.10%)
     
  • Silver

    21.17
    -0.00 (-0.01%)
     
  • EUR/USD

    1.0586
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • Vix

    26.95
    -0.28 (-1.03%)
     
  • GBP/USD

    1.2278
    +0.0008 (+0.06%)
     
  • USD/JPY

    135.4350
    -0.0110 (-0.01%)
     
  • BTC-USD

    20,773.38
    -406.87 (-1.92%)
     
  • CMC Crypto 200

    452.04
    -9.76 (-2.11%)
     
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • Nikkei 225

    27,006.33
    +135.06 (+0.50%)
     

Why Eli Lilly Stock Climbed Today

·1 min read
Why Eli Lilly Stock Climbed Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Eli Lilly (NYSE: LLY) rose on Monday after the U.S. Food and Drug Administration (FDA) approved the pharmaceutical giant's new diabetes treatment, tirzepatide. As of 1:50 p.m. ET, Eli Lilly's stock price was up more than 3%. A phase 3 clinical trial showed tirzepatide to reduce A1C -- a key measure of average blood sugar levels -- better than existing treatment options.